This review focuses on the potential applications of CA and CS for Alzheimer’s disease (AD), Parkinson’s disease (PD), and coronavirus disease 2019 (COVID-19), in part via inhibition of the NLRP3 inflammasome. The gene discussed is NLRP3; the disease is early-onset autosomal dominant Alzheimer disease.